Sepsivac

Sepsivac is a novel drug developed by Cadila Pharmaceuticals to treat patients of gram-negative sepsis patients.  As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.[1]

Mechanism

In patients with sepsis, in response to an infection, a lot of pro-inflammatory and anti-inflammatory cytokines are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. Immunomodulator drugs such as Sepsivac regulate this host immune response.[2] Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.[3]

Sepsivac and COVID-19

Scientists at CSIR found similarities between the clinical characteristics of patients suffering from gram-negative sepsis and COVID-19. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled clinical trial to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients.[1] The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate.[4] The clinical trials will be conducted at premier national hospitals like PGIMER Chandigarh, AIIMS New Delhi and AIIMS, Bhopal.[5]

gollark: More latererer search UI.
gollark: Even more slightly laterer search UI.
gollark: Slightly later search UI.
gollark: Initial search UI.
gollark: Exciting news: minoteaur development.

References
  1. Singh, Jyoti (2020-04-22). "Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus". The Wire Science. Retrieved 2020-04-28.
  2. Koshy, Jacob (2020-04-21). "Coronavirus | Drug for sepsis to be tested for COVID-19". The Hindu. ISSN 0971-751X. Retrieved 2020-04-28.
  3. Paliath, Shreehari (2020-04-22). "Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients |". www.indiaspend.com. Retrieved 2020-04-28.
  4. "Sepsivac to be tested for COVID-19 treatment". The New Indian Express. Retrieved 2020-04-28.
  5. "50-yr-old bacteria drug makes a comeback in fight against coronavirus". Deccan Herald. 2020-04-23. Retrieved 2020-04-28.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.